NKARTA INC (NKTX) Stock News

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta posts a smaller Q1 loss than expected and maintains strong cash reserves while analysts debate its trial strategy and market position.

This Alcoa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday

Mentions: AA GROV COLD LAZR

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus...

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Why Nkarta Stock Is Soaring Today

One analyst is now more bullish about this clinical-stage biotech stock.

Mentions: RJF

NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Nkarta (NASDAQ:NKTX) just reported results for the second quarter of 2024.Nkart...

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX Stock Earnings: Nkarta Beats EPS for Q2 2024

NKTX stock results show that Nkarta beat analyst estimates for earnings per share the second quarter of 2024.

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological...

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored...

Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Nkarta to Participate in an Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

First patient dosed in each of Ntrust-1 and investigator-sponsored clinical trial (IST) of NKX019; enrollment ongoing in both studiesEnrollment in Ntrust-2...

Nkarta Reports Third Quarter 2024 Financial Results and Corporate Highlights

Nkarta to Participate in Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Correction: Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Enrollment expected to initiate by year-end 2024 in second clinical trial of NKX019 in autoimmune disease, Ntrust-2, for treatment of systemic sclerosis,...

Nkarta Reports Second Quarter 2024 Financial Results and Corporate Highlights

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

3 Undervalued Stocks Primed for a 2X Return

Discover compelling investment opportunities with top undervalued stocks for high returns leading in healthcare and software.

Mentions: NOTV RPD